Core Viewpoint - WuXi AppTec plans to issue new H shares to accelerate global expansion and capacity building, aiming to enhance long-term development and customer service [1][2][3] Summary by Sections Issuance Plan - The company intends to issue H shares, with each share having a par value of RMB 1.00 [1] - The issuance will be directed towards at least six independent overseas investors and qualified domestic investors [2] - The number of shares to be issued will not exceed 20% of the existing H shares, amounting to a maximum of 73,800,000 shares [3] Pricing and Fund Utilization - The proposed issue price is set at HKD 104.27 per share, determined based on market conditions and comparable company valuations [3] - The net proceeds from the issuance, estimated at approximately HKD 7.65 billion, will be allocated as follows: about 90% for global expansion and capacity building, and about 10% for general operational funding [3] Decision-Making Process - The resolution for the issuance is valid for 12 months from the board's approval date [4][5] - The company will seek approval from the Hong Kong Stock Exchange for the listing of the new shares and will file with the China Securities Regulatory Commission [6]

Major Events - JD Group-SW (09618) has decided to make a voluntary public acquisition offer to CECONOMY and establish a strategic investment partnership [1] - Zhonghui Biological-B (02627) plans to conduct an IPO from July 31 to August 5, aiming to globally offer 33.4426 million H-shares [1] - WuXi AppTec (02359) intends to place 73.8 million new H-shares at a discount of approximately 6.90%, raising about HKD 7.65 billion [1] - Weihai Bank (09677) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly HKD 3 billion [1] - HSBC Holdings (00005) plans to repurchase up to USD 3 billion of ordinary shares [1] - Joy City Property (00207) proposes a share buyback through an agreement arrangement, with resumption of trading on August 1 [1] Operating Performance - MGM China (02282) reported total revenue of HKD 16.661 billion for the first half, an increase of 2.73% year-on-year [1] - Standard Chartered Group (02888) released interim results with a profit attributable to shareholders of USD 3.065 billion, a year-on-year increase of 41% [1] - Autohome-S (02518) reported a net profit attributable to the parent of RMB 416 million in the second quarter, with online marketing and other business revenues increasing by 20.5% year-on-year [1] - Tongguan Gold (00340) issued a positive profit alert, expecting a mid-term profit attributable to shareholders of approximately HKD 330 million to HKD 360 million, a year-on-year increase of about 259% to 291% [1] - Qingdao Bank (03866) reported a net profit attributable to the parent of RMB 3.065 billion for the first half, a year-on-year increase of 16.05% [1] - Faraday (09638) announced interim results with a profit attributable to shareholders of EUR 4.3454 million, a year-on-year decrease of 0.92% [1] - Budweiser APAC (01876) released interim results with a profit attributable to shareholders of USD 409 million, a year-on-year decrease of 24.4% [1]

每经AI快讯，7月31日，药明康德在港交所公告，根据一般授权配售新H股，配股价为每股104.27港 元。 ...

Core Viewpoint - WuXi AppTec reported strong financial performance in the first half of the year, with significant revenue and profit growth, driven by robust demand in its core business segments and strategic operational improvements [3][4][5]. Financial Performance - The company achieved operating revenue of 20.799 billion yuan, a year-on-year increase of 20.64% [3]. - Net profit attributable to shareholders reached 8.561 billion yuan, up 101.92% year-on-year [3]. - The net profit excluding non-recurring items was 5.582 billion yuan, reflecting a growth of 26.47% [3]. Quarterly Highlights - In Q2, WuXi AppTec's revenue surpassed 11.145 billion yuan for the first time, marking a historical milestone [4]. - The net profit for Q2 was 4.889 billion yuan, also a record for the same period [4]. - The company anticipates continued strong performance in Q3 and Q4, with quarterly revenues expected to remain above 10 billion yuan [4]. Business Segments - The chemical business remains the cornerstone of WuXi AppTec's revenue, accounting for nearly 80% of total income, with revenue of 16.301 billion yuan, a year-on-year increase of 33.51% [5]. - The small molecule process development and manufacturing (D&M) segment generated 8.68 billion yuan, growing 17.5% year-on-year [5]. Order Backlog - As of June 30, 2025, the company had a backlog of orders amounting to 56.69 billion yuan, a 37.2% increase year-on-year [5]. Profit Growth Drivers - Profit growth was attributed to a focus on the CRDMO business model, operational efficiency improvements, and increased capacity from late-stage clinical and commercialization projects [6]. - The sale of shares in WuXi XDC Cayman Inc. contributed significantly to profit, with investment income reaching 3.669 billion yuan, a 163-fold increase year-on-year [8]. Cash Flow and Dividends - The net cash flow from operating activities was 7.431 billion yuan, up 49.63% year-on-year [8]. - The board approved the company's first interim dividend, proposing a cash dividend of 3.5 yuan per 10 shares, totaling approximately 1 billion yuan [10]. - The company has completed cash dividends totaling 3.84 billion yuan in the first half of the year and is executing a share buyback plan valued at 1 billion yuan [12].

Core Viewpoint - The article discusses the current state of the investment market, focusing on the performance of various sectors and the implications of regulatory changes on investment strategies. Group 1: Insurance and Investment Strategies - The podcast highlights the rapid growth of the insurance sector since 2022 and the underlying logic behind this trend [5] - It discusses the regulatory push to lower the insurance preset interest rates starting in 2024, which is expected to impact investment decisions [6] - The assessment of state-owned insurance companies' evaluation mechanisms is seen as beneficial for the stock market [6] - Recommendations for investment allocation are provided, suggesting diversification and balanced approaches rather than chasing hot stocks [20] Group 2: Market Performance and Trends - The equity market experienced significant declines, with over 80% of stocks falling and a median drop of approximately 1.45% [10] - External factors, particularly U.S.-China trade negotiations, are influencing market sentiment, with the U.S. gaining a psychological advantage [12] - Internal market dynamics show a cooling of "anti-involution" trading, leading to declines in previously high-performing sectors like steel and coal [14] - Commodity prices have returned to previous levels, indicating a correction in the market [15] Group 3: Specific Stock Insights - The stock of a pharmaceutical company, referred to as "药X," fell by 5.6% following a planned share placement, reflecting market reactions to corporate actions [21] - The article suggests maintaining good relations with company management for better insights into stock movements [22] Group 4: Future Outlook and Recommendations - The company advises waiting for upcoming earnings reports from major firms like Apple before making further investment decisions [23] - It notes that some fund companies have relaxed purchase limits on certain products, indicating a shift in market accessibility [24]

根据公司与Morgan Stanley Asia Limited（独家整体协调人、独家全球协调人及牵头账簿管理人）、 Citigroup Global Markets Limited（联席账簿管理人）、Goldman Sachs (Asia) L.L.C.（联席账簿管理人） 和The Hongkong and Shanghai Banking Corporation Limited（联席账簿管理人）就本次发行签署的配售协 议，本次配售股数拟定为73,800,000股H股，若香港联合交易所有限公司对上述发行数量上限有所调 整，以相关监管机构认可（如适用）的数据为准。 根据配售协议，本次发行的配售价格拟定为104.27港元/股。较最新收盘价112港元/股折价6.9%。 中国经济网北京7月31日讯 药明康德（603259）(603259.SH)A股今日收报96.27元，跌幅2.61%；药明康 德（02359.HK）港股今日收报105.70港元，跌幅5.63%。 药明康德今早披露关于根据一般性授权配售新H股的公告称，经公司第三届董事会第二十四次会议审议 批准，公司拟根据2024年年度股东大会审议通过的《关于给予董事会 ...

（股份代號：2359） WUXI APPTEC CO., LTD.* 無錫藥明康德新藥開發股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 董事名單及其角色與職能 本公司董事會（「董事會」）成員載列如下： * 僅供識別 – 1 – 董事會下設四個委員會。各委員會的成員如下： 審計委員會 盧韶華女士 （主席） 俞衛博士 張新博士 薪酬與考核委員會 執行董事 李革博士 （董事長兼首席執行官） 陳民章博士 （聯席首席執行官） 楊青博士 （聯席首席執行官） 張朝暉先生 非執行董事 童小幪先生 吳亦兵博士 獨立非執行董事 盧韶華女士 俞衛博士 張新博士 詹智玲女士 冷雪松先生 提名委員會 冷雪松先生 （主席） 李革博士 詹智玲女士 香港，2025年7月31日 – 2 – 詹智玲女士 （主席） 張新博士 冷雪松先生 戰略委員會 李革博士 （主席） 陳民章博士 童小幪先生 吳亦兵博士 俞衛博士 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 根據一般授權配售新H股 獨家整體協調人、獨家全球協調人及牽頭賬簿管理人 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司 法權區內刊發或派發。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非，亦不構成於美國（定義見1933年《美國證券法》（「《證券法》」）S規例）出售證券的 要約或邀請及其任何部分。本公告或其任何內容或其副本亦不得攜進美國境內或於美國境內 或在刊發或派發本公告屬違法的任何其他司法權區內直接或間接派發。除非本公告所指證券 根據《證券法》辦理登記或獲豁免遵守《證券法》的登記規定，否則有關證券未曾亦不會根據《證 券法》登記，且不得在美國境內提呈發售、出售或以其他方式轉讓。本公司並無計劃在美國 登記本公告所述任何證券或在美國公開發售任何證券。 WUXI APPTEC C ...

（文章来源：每日经济新闻） 开源证券7月31日发布研报称，给予药明康德（603259.SH，最新价：96.32元）买入评级。评级理由主 要包括：1）2025H1 业绩超预期，TIDES 业务增速强劲打开成长空间；2）小分子D&M管线持续扩张， TIDES业务强劲增长；3）临床业务稳健发展，着力搭建新分子种类相关生物学平台。风险提示：中美 贸易摩擦，市场竞争加剧，环保和安全生产风险。 ...

近日，药明康德发布了2025年中期业绩，亮眼的成绩单再次验证了药明康德非凡的内生增长力。 三个层面可以看出药明康德强劲的增长态势： 营收：上半年公司整体营业收入208.0亿元，同比+20.6%；其中持续经营业务收入204.1亿元，同比 +24.2%。 在手订单：截至6月底，持续经营业务在手订单566.9亿元，同比+37.2%。 药明康德在巨大的体量下依然能够保持营收、利润与在手订单的双位数的增长，整体发展态势高于行业 平均水平，再次印证了其CRDMO模式的发展韧性，也离不开管理决策的预见性和正确性。 药明康德有哪些增长的秘诀？ 全面赋能，紧抓客户需求 在全球医药研发成本持续上升、成功率依然不高的背景下，能够帮助客户提高效率、降低成本的商业模 式将具有持久生命力。因此，面对外部挑战，药明康德始终不断强化"一体化、端到端"的服务能力，紧 抓客户需求。 药明康德多年以来打造的CRDMO模式，以全流程覆盖的一体化优势，从源头锁定行业潜力新药分子， 夯实客户粘性，逐步打造了后期的规模效应。 一直以来，药明康德以高度可靠的质量体系和交付效率成为了诸多全球大型药企供应链的重要组成部 分。即使在极具挑战的2024年，药明康德 ...